Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1152W HIGH $13.78
Volume
197.41 K
Value Traded
3.02 M
Short % Float
16.94%
-7.75%Week
-22.67%1 Month
+5,722.04%3 Month
+2,312.7%6 Month
-97.75%5 Year
-98.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
60.43 M
EPS (TTM)
-20.47
P/E Ratio
-
Ent. Value
3.40 M
Total Shares
6.12 M
Float Shares
5.60 M
Insiders
8.29%
Institutions
71.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GOSS Catalyst Timeline
Dated clinical, regulatory and corporate events for Gossamer Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gossamer Bio, Inc.
212Total events
10Upcoming
55Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Reverse Stock SplitCorporate
Common stock expected to begin trading on split-adjusted basis on Nasdaq
●NDA SubmissionSeralutinibFiledRegulatory Filing
Gossamer submits NDA to FDA for seralutinib in PAH
pulmonary arterial hypertensionsource ↗
◆Timing GuidanceSeralutinibFiledPresentation
Planned NDA submission for seralutinib in PAH
pulmonary arterial hypertension (PAH)source ↗
▲Topline ReadoutSeralutinibFiledClinical Data
PROSERA CT FRI substudy topline results announced
pulmonary arterial hypertensionsource ↗
●Equity OfferingCorporate
Commencement of exchange offer for 5.00% Convertible Senior Notes due 2027
▲Partnership / LicenseSeralutinibFiledCorporate
Gossamer reacquires worldwide rights to seralutinib from Chiesi
▲FDA Feedback ReceivedSeralutinibFiledFDA Meeting
Receipt of official FDA meeting minutes from Pre-NDA meeting
pulmonary arterial hypertension (PAH)source ↗
▲Milestone PaymentSeralutinibFiledCorporate
Chiesi to make one-time $5 million payment to Gossamer
●Equity OfferingCorporate
Stockholders approve convertible note exchange and reverse stock split
▲Corporate ApprovalCorporate
Stockholders approved proposals related to convertible note exchange and reverse stock split
●Quarterly UpdateCorporate
Preliminary cash balance of approximately $57 million as of June 30, 2026
◆Quarterly UpdateCorporate
Extension of early tender date for exchange offer and consent solicitation for convertible notes
●FDA Feedback ReceivedSeralutinibFiledFDA Meeting
Receipt of official FDA Pre-NDA Type B meeting minutes
pulmonary arterial hypertension (PAH)source ↗
◆Type C MeetingSeralutinibFiledFDA Meeting
Planned Type C meeting with FDA to discuss PROSERA data and regulatory path
pulmonary arterial hypertension (PAH)source ↗
●Pre NDA MeetingSeralutinibFiledFDA Meeting
Pre-NDA Type B meeting with FDA for seralutinib in PAH
pulmonary arterial hypertensionsource ↗
▲Partnership / LicenseSeralutinibFiledCorporate
Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi
pulmonary arterial hypertension (PAH)source ↗
▲Milestone PaymentSeralutinibFiledCorporate
Chiesi one-time $5 million payment to Gossamer under termination agreement
pulmonary arterial hypertension (PAH)source ↗
▲Debt Royalty FinancingCorporate
Exchange of 2027 Notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030
▲Topline ReadoutSeralutinibFiledClinical Data
Positive PROSERA CT FRI substudy topline results announced
pulmonary arterial hypertensionsource ↗
●Equity OfferingCorporate
Commencement of exchange offer for 5.00% Convertible Senior Notes due 2027
▼Topline ReadoutSeralutinibFiledClinical Data
PROSERA Phase 3 topline results: narrowly missed primary endpoint
pulmonary arterial hypertension (PAH)source ↗
▼Enrollment PausedSeralutinibFiledTrial
Enrollment paused in Phase 3 SERANATA Study in PH-ILD
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
◆Additional DataSeralutinibFiledClinical Data
PROSERA CT functional respiratory imaging substudy results expected
pulmonary arterial hypertensionsource ↗
▼Primary Endpoint MissedClinical Data
Phase 3 PROSERA study failed to meet primary endpoint
pulmonary arterial hypertensionsource ↗
▼Trial DiscontinuedTrial
Phase 3 PROSERA study failed to meet primary endpoint
pulmonary arterial hypertensionsource ↗
◆Topline ReadoutSeralutinibFiledClinical Data
Topline results from Phase 3 PROSERA study of seralutinib in PAH
pulmonary arterial hypertensionsource ↗
▼Primary Endpoint MissedSeralutinibFiledClinical Data
Primary endpoint missed in PROSERA trial
pulmonary arterial hypertensionsource ↗
▼Enrollment PausedSeralutinibFiledTrial
Pausing enrollment into SERANATA study to evaluate impact of PROSERA results
pulmonary hypertension associated with interstitial lung diseasesource ↗
◆Oral PresentationSeralutinibFiledPresentation
Conference call and webcast to discuss PROSERA topline results
pulmonary arterial hypertensionsource ↗
▼Topline ReadoutSeralutinibFiledClinical Data
Topline results from PROSERA Phase 3 study of seralutinib in PAH
pulmonary arterial hypertension (PAH)source ↗
▼Primary Endpoint MissedSeralutinibFiledClinical Data
PROSERA primary endpoint missed
pulmonary arterial hypertension (PAH)source ↗
▼Equity OfferingCorporate
Second closing of private placement with $125 million gross proceeds
◆Topline ReadoutSeralutinibFiledClinical Data
Topline data readout from PROSERA Phase 3 study in PAH
pulmonary arterial hypertension (PAH)source ↗
◆Trial InitiationSeralutinibFiledTrial
First site activations for SERANATA Phase 3 study expected in Q4 2025
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
●Oral PresentationSeralutinibFiledPresentation
Oral presentation at ERS Congress 2025 on seralutinib targeting fibrotic pathways in IPF
idiopathic pulmonary fibrosissource ↗
●Poster PresentationSeralutinibFiledPresentation
Four poster presentations at ERS Congress 2025 on seralutinib
pulmonary hypertensionsource ↗
▲Partnership / LicenseCorporate
Strategic option agreement to acquire Respira and inhaled vardenafil
pulmonary hypertensionsource ↗
Past FDA Catalysts and PDUFA Decisions
How GOSS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | seralutinib (GB002) | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 83%
Micro Cap(rank 546 of 658)
Percentile Rank
Gossamer Bio, Inc. faces pipeline headwinds (25/100), with $309M risk-adjusted pipeline value, led by Seralutinib in Pulmonary Artery Hypertension (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seralutinib Small moleculeNCT04816604 | Pulmonary Arterial Hypertension | Phase 3 | TERMINATED | 802 | Sep 9, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every GOSS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Gossamer Bio | Phase 3 | 2026-05-07 | failed to meet the primary endpointRead More | GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallStRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aranda RichardOfficer (Chief Medical Officer) | Disposition | -562,500 | $0.00 | 03/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GOSS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 0.1 % (-66.7 %) | 1.27 M | 7.75 M |
GOSS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GOSS ranks across every disease it competes in
Competitive Position is a premium feature
See how GOSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGOSS News
GOSSGossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio has submitted a New Drug Application to the U.S. FDA for seralutinib, aimed at treating pulmonary arterial hypertension (PAH). This marks a significant step in the drug's development and potential commercialization. The application reflects the company's commitment to addressing serious health conditions associated with pulmonary hypertension.
Read more →GOSS▲ +8.9%on this news
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio has appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026. Ciongoli will also be a member of the Audit Committee. This appointment is expected to enhance the company's leadership and governance as it focuses on developing treatments for pulmonary arterial hypertension and related conditions.
Read more →GOSS▼ -5.8%on this newsshared move
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split to enhance its stock structure. The company has filed a Certificate of Amendment with the Delaware Secretary of State. This move is aimed at improving market perception and potentially attracting more institutional investors.
Read more →GOSS▼ -11.2%on this news· ran to -26% by day 3shared move
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split of its common stock, which is intended to reduce the number of outstanding shares. This decision comes amid the company's focus on developing seralutinib for pulmonary arterial hypertension. The board aims to enhance the stock's marketability and align it with compliance requirements.
Read more →GOSSGossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio, a clinical-stage biopharmaceutical company, will present at the Cantor Global Healthcare Conference scheduled for September 9-11, 2026. The company focuses on developing seralutinib for pulmonary arterial hypertension and related conditions. This event is expected to provide an opportunity for Gossamer to showcase its advancements and engage with investors.
Read more →GOSSGossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio has announced a significant private placement financing of up to $250 million, which includes $150 million in committed capital. This funding is intended to support the development of seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as it progresses towards potential FDA approval.
Read more →GOSS▼ -9.5%on this news
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio, a clinical-stage biopharmaceutical firm, announced its financial results for the second quarter of 2026. The company is focused on developing seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The update reflects Gossamer's ongoing efforts to strengthen its business.
Read more →GOSSKuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
Kuehn Law is investigating Gossamer Bio, Inc. for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit claims that the company misrepresented details about its Phase 3 PROSERA study for seralutinib, particularly regarding the study's design and control of placebo responses. This alleged misinformation may have led to inflated stock prices, impacting investors negatively.
Read more →GOSS▲ +46.6%on this news
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Gossamer Bio has announced significant regulatory and corporate updates, including positive feedback from the FDA following a Pre-NDA Type B meeting. The company has also reacquired worldwide rights to seralutinib, which is intended for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. These developments signal a promising direction for Gossamer's future in the biopharmaceutical market.
Read more →GOSSGossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Gossamer Bio, Inc. has announced the conversion rate for its 7.50% convertible senior secured first lien notes due in 2030, along with the exercise price for purchase warrants. This announcement is part of the company's ongoing financial strategy. Further details regarding the implications of these changes were not provided in the article.
Read more →GOSS▲ +6.7%on this news
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the final tender results for its exchange offer and consent solicitation concerning existing convertible notes. The announcement provides details about the completion of the exchange offer, but lacks specific financial figures or implications for stakeholders. The company aims to streamline its capital structure through this initiative.
Read more →GOSS▼ -5.9%on this news· ran to -17% by day 3
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced the early tender results and early settlement for its exchange offer and consent solicitation related to existing convertible notes. The announcement indicates a strategic move by the company but lacks detailed information on the implications or outcomes of the offer.
Read more →GOSSGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. has announced an extension of the early tender date for its exchange offer and consent solicitation related to existing convertible notes. This decision is part of the company's ongoing financial strategies. Further details regarding the implications of this extension were not provided in the announcement.
Read more →GOSS▼ -43.3%on this news
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Gossamer Bio, Inc. has announced an exchange offer and consent solicitation aimed at eliminating over $120 million of debt. This initiative has received support from existing noteholders, indicating confidence in the company's financial strategy. The move is part of Gossamer's efforts to strengthen its balance sheet and improve financial stability.
Read more →GOSS▼ -43.3%on this news
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio has released its financial results for the first quarter of 2026 along with a business update. The details of the financial performance and any strategic plans or developments were not disclosed in the article. Further insights into the company's direction or upcoming initiatives were also not provided.
Read more →GOSSGossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
Gossamer Bio has scheduled the announcement of its first quarter 2026 financial results. The company will host a conference call and webcast on May 18, 2026, to discuss the results. Further details regarding the financial performance and future outlook may be shared during this event.
Read more →GOSS▼ -8%on this news· ran to -21% by day 3
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio announced its financial results for Q4 and full year 2025, highlighting a focus on the PROSERA Phase 3 trial results. The company is engaging with the FDA while pausing enrollment in the SERANATA Study. A workforce reduction has been implemented to prioritize resources. Despite challenges, seralutinib is considered an active treatment for advanced pulmonary arterial hypertension.
Read more →GOSSGossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
Gossamer Bio's seralutinib failed to show significant improvement in a Phase 3 trial for pulmonary arterial hypertension, leading to an 80% drop in stock price. Despite some positive signals in high-risk patients, analysts express doubt about the drug's market viability. Gossamer plans to consult with the FDA regarding future steps, while suspending enrollment in another study.
Read more →GOSS▼ -80.1%on this newsshared move
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio announced topline results from the Phase 3 PROSERA Study of seralutinib for pulmonary arterial hypertension (PAH). Although the primary endpoint did not meet the stringent statistical threshold, seralutinib demonstrated significant improvements in six-minute walk distance (6MWD) and showed efficacy in high-risk patient subgroups. The company plans to discuss these results with the FDA for potential next steps.
Read more →About Gossamer Bio, Inc.
Headquarters3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next GOSS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime